Effect of biologics targeting interleukin-23/-17 axis on subclinical atherosclerosis: results of a pilot study.

Maruška MarovtP B MarkoM PirnatR Ekart

Published in: Clinical and experimental dermatology (2020)

Systemic treatment of patients with a psoriatic disease with biologics targeting the IL-23/IL-17 axis has a possibly neutral effect on atherosclerosis. Additional studies are needed to assess the impact of newer biologic treatments on atherosclerosis.

Keyphrases

cardiovascular disease
rheumatoid arthritis
cancer therapy
disease activity
ankylosing spondylitis
type diabetes
drug delivery
combination therapy
systemic lupus erythematosus